Compounded semaglutide and the Ivím weight loss program

A weekly compounded semaglutide injection to lose weight, curb hunger, and regulate blood sugar.*

Starting at $99/mo

FDA notice on Wegovy®/Ozempic® shortage: On February 21st, 2025, the U.S. Food and Drug Administration determined that the shortage of semaglutide injection, a glucagon-like peptide 1 (GLP-1) medication, has ended. Patients may continue receiving essential copies through April 22nd, 2025, from 503A compounding pharmacies and through May 22nd, 2025, from 503B compounding pharmacies. Beyond these dates, patients may explore personalized treatments and dosing options through Ivim Health to support their unique health and wellness goals.

At Ivim Health, we are deeply committed to supporting our patients and empowering our providers to prioritize your health and wellness. We strive to help you discover the best available therapies and personalize them to align with your individual goals.

As part of your Ivim membership, we are working diligently to ensure access to safe and effective therapies that support your overall metabolic health. This includes facilitating insurance access to trusted name-brand treatments, providing exclusive Ivim discounts on name-brand medications, and offering customized compounded solutions tailored to your needs.

*Compounded semaglutide may be prescribed based on personal weight loss needs. While federal law allows the prescription of compounded drugs, they are not FDA-approved and do not undergo safety, effectiveness, or manufacturing review. For additional safety information, please see our Safety Page.

Semaglutide is presently only available as prescription brand name products, Wegovy® and Ozempic®*. Compounded semaglutide belongs to the same class of drugs known as GLP-1 receptor agonists. Individuals may be prescribed compounded semaglutide for various reasons, such as requiring a unique formulation, facing insurance denial for brand name coverage, seeking cost savings, or experiencing a local drug shortage.

Drug compounding is legal and a well-accepted practice in the United States. It is the process of combining, mixing, or changing ingredients to create a medication specific to the needs of an individual patient. Ivím only selects FDA-inspected, state-regulated compounding pharmacies that meet regulatory board standards for quality and safety to fulfill our compounded semaglutide prescriptions for our patients.

Your Ivím medical provider will evaluate your eligibility based on your medical questionnaire and discuss your compounded GLP-1 medication options. Compounded tirzepatide may be prescribed based on your personal weight loss needs. Individuals may be prescribed compounded semaglutide for various reasons, such as requiring a unique formulation, facing insurance denial for brand name coverage, seeking cost savings, or experiencing a local drug shortage.

Compounded semaglutide medication is not covered by insurance, but Ivím provides affordable pricing options to ensure your weight loss goals stay within reach. Often, compounded semaglutide medication will be up to 85% less than the retail price of the name brand FDA-approved GLP-1 medications like Ozempic® and Wegovy®.

Yes! Compounded semaglutide medication can be paid for with your HSA or FSA card.

*Disclaimer: Wegovy® and Ozempic® are both registered trademarks of Novo Nordisk. Ivím is not affiliated with Novo Nordisk.